SG11201503456TA - Treatment of cancer with pomalidomide in a renally impaired subject - Google Patents
Treatment of cancer with pomalidomide in a renally impaired subjectInfo
- Publication number
- SG11201503456TA SG11201503456TA SG11201503456TA SG11201503456TA SG11201503456TA SG 11201503456T A SG11201503456T A SG 11201503456TA SG 11201503456T A SG11201503456T A SG 11201503456TA SG 11201503456T A SG11201503456T A SG 11201503456TA SG 11201503456T A SG11201503456T A SG 11201503456TA
- Authority
- SG
- Singapore
- Prior art keywords
- pomalidomide
- cancer
- treatment
- impaired subject
- renally impaired
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261722722P | 2012-11-05 | 2012-11-05 | |
| US201361764466P | 2013-02-13 | 2013-02-13 | |
| PCT/US2013/068237 WO2014071280A1 (en) | 2012-11-05 | 2013-11-04 | Treatment of cancer with pomalidomide in a renally impaired subject |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201503456TA true SG11201503456TA (en) | 2015-05-28 |
Family
ID=50628132
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201503456TA SG11201503456TA (en) | 2012-11-05 | 2013-11-04 | Treatment of cancer with pomalidomide in a renally impaired subject |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20150297579A1 (en) |
| EP (1) | EP2914112A4 (en) |
| JP (1) | JP2015535291A (en) |
| CN (1) | CN104902754A (en) |
| AU (1) | AU2013337352A1 (en) |
| BR (1) | BR112015010039A2 (en) |
| CA (1) | CA2889987A1 (en) |
| EA (1) | EA201590883A1 (en) |
| HK (1) | HK1214552A1 (en) |
| IL (1) | IL238563A0 (en) |
| MX (1) | MX2015005548A (en) |
| NI (1) | NI201500063A (en) |
| PH (1) | PH12015501002A1 (en) |
| SG (1) | SG11201503456TA (en) |
| WO (1) | WO2014071280A1 (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014248263A1 (en) * | 2013-04-02 | 2015-10-15 | Celgene Corporation | Methods and compositions using 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment and management of central nervous system cancers |
| EP3718569B1 (en) * | 2015-05-22 | 2023-05-03 | Translational Drug Development, LLC | Benzamide and active compound compositions and methods of use |
| WO2019051125A1 (en) * | 2017-09-06 | 2019-03-14 | Translational Drug Development, Llc | Aminobenzimidazole derivatives, treatments, and methods of inhibiting histone deacetylase |
| CN105456232A (en) * | 2015-09-08 | 2016-04-06 | 刘剑 | Pomalidomide instant film agent and preparation method thereof |
| CN109071460B (en) * | 2016-03-02 | 2022-08-09 | 转化药物开发有限责任公司 | Aminobenzimidazole derivatives |
| WO2018013689A1 (en) * | 2016-07-13 | 2018-01-18 | Celgene Corporation | Solid dispersions and solid forms comprising 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione, method of preparation and use thereof |
| CN108721304B (en) * | 2017-04-17 | 2020-10-16 | 北京大学 | Pharmaceutical composition for treating tumor and application thereof |
| GB202012160D0 (en) * | 2020-08-05 | 2020-09-16 | Vicore Pharma Ab | New compositions |
| WO2023158486A2 (en) * | 2022-02-15 | 2023-08-24 | The Broad Institute, Inc. | Cell-type specific targeting contractile injection system |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7968569B2 (en) * | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| JP5339588B2 (en) * | 2008-11-10 | 2013-11-13 | 国立大学法人 新潟大学 | A therapeutic drug for schizophrenia containing thalidomide or its derivatives as an active ingredient |
| JP5553275B2 (en) * | 2010-03-31 | 2014-07-16 | 国立大学法人金沢大学 | Metal complex and anticancer agent containing this as active ingredient |
| WO2012145309A1 (en) * | 2011-04-18 | 2012-10-26 | Celgene Corporation | Biomarkers for the treatment of multiple myeloma |
| WO2012149299A2 (en) * | 2011-04-29 | 2012-11-01 | Celgene Corporaiton | Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor |
-
2013
- 2013-11-04 JP JP2015540844A patent/JP2015535291A/en active Pending
- 2013-11-04 EA EA201590883A patent/EA201590883A1/en unknown
- 2013-11-04 EP EP13850977.3A patent/EP2914112A4/en not_active Withdrawn
- 2013-11-04 MX MX2015005548A patent/MX2015005548A/en unknown
- 2013-11-04 SG SG11201503456TA patent/SG11201503456TA/en unknown
- 2013-11-04 US US14/440,333 patent/US20150297579A1/en not_active Abandoned
- 2013-11-04 WO PCT/US2013/068237 patent/WO2014071280A1/en active Application Filing
- 2013-11-04 CA CA2889987A patent/CA2889987A1/en not_active Abandoned
- 2013-11-04 BR BR112015010039A patent/BR112015010039A2/en not_active IP Right Cessation
- 2013-11-04 CN CN201380069405.4A patent/CN104902754A/en active Pending
- 2013-11-04 AU AU2013337352A patent/AU2013337352A1/en not_active Abandoned
-
2015
- 2015-04-30 IL IL238563A patent/IL238563A0/en unknown
- 2015-05-04 NI NI201500063A patent/NI201500063A/en unknown
- 2015-05-05 PH PH12015501002A patent/PH12015501002A1/en unknown
-
2016
- 2016-03-07 HK HK16102558.2A patent/HK1214552A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20150297579A1 (en) | 2015-10-22 |
| AU2013337352A1 (en) | 2015-05-21 |
| HK1214552A1 (en) | 2016-07-29 |
| EP2914112A1 (en) | 2015-09-09 |
| PH12015501002A1 (en) | 2015-07-27 |
| MX2015005548A (en) | 2016-01-15 |
| BR112015010039A2 (en) | 2017-07-11 |
| CA2889987A1 (en) | 2014-05-08 |
| JP2015535291A (en) | 2015-12-10 |
| CN104902754A (en) | 2015-09-09 |
| EP2914112A4 (en) | 2016-06-15 |
| EA201590883A1 (en) | 2015-09-30 |
| IL238563A0 (en) | 2015-06-30 |
| WO2014071280A1 (en) | 2014-05-08 |
| NI201500063A (en) | 2015-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL267242B (en) | Cancer treatment | |
| HK1213444A1 (en) | Cancer treatments | |
| HK1214552A1 (en) | Treatment of cancer with pomalidomide in a renally impaired subject | |
| EP2819703A4 (en) | Pain treatment | |
| EP2906208A4 (en) | Therapeutic treatment | |
| HK1214128A1 (en) | Treatment of cancer | |
| HK1205254A1 (en) | Methods of treatment of cancer | |
| GB201217892D0 (en) | Treatment of cancer | |
| HK1210023A1 (en) | Cancer treatment | |
| HK1204956A1 (en) | Treatment of cancer | |
| SI2892925T1 (en) | Combination treatment of cancer | |
| GB201204981D0 (en) | Pre-harvest treatment | |
| HK1214505A1 (en) | Treatment regimens | |
| GB201222563D0 (en) | Cancer treatment | |
| GB201217890D0 (en) | Treatment of cancer | |
| GB2498582B (en) | Improvements in medical identity bracelets | |
| GB201322958D0 (en) | Uses of oligouronates in cancer treatment | |
| GB201222950D0 (en) | Combination treatment of cancer | |
| GB201222949D0 (en) | Combination Treatment of Cancer | |
| GB201208296D0 (en) | Treatment of cancer | |
| GB201206294D0 (en) | Improved toenail treatment | |
| GB201211135D0 (en) | Treatment | |
| GB201208690D0 (en) | Treatment |